Case Report

Neupogen (Filgrastim) Induced Acute Hematuria/Proteinuria with 3 Days of Use in a 7-Year-old Boy Diagnosed as Aplastic Anemia

Sohail Azam1, Hassan Eliwan2, Fatima Eltayeb Hago3, Al Husein Mohammed Chyad Hammoudi3

1Department of Inpatient Pharmacy, Dr Sulaiman Al-Habib Hospital, Arryyan, Riyadh, Saudi Arabia
2Department of Pediatric, Dr Sulaiman Al-Habib Hospital, Arryyan, Riyadh, Saudi Arabia
3Department of Clinical Therapies, University of Limerick, Limerick, Ireland

1. INTRODUCTION

Filgrastim is a recombinant human Granulocyte Colony-stimulating Factor (G-CSF) approved by the US Food and Drug Administration [1]. It is used to treat patients with neutropenia caused by chemotherapy [2–5], human immunodeficiency virus infection [6], bone marrow transplant [7–9], or in cases of congenital [10,11], cyclic [12,13], or idiopathic neutropenias [2,11]. It is a hematopoietic growth factor that influences leukopoiesis [12–14], and affects the proliferation and differentiation of neutrophils within the bone marrow [15,16] and possibly other sites (e.g., spleen) [17,18]. It binds directly to G-CSF receptors on neutrophil progenitor target cell surfaces [19,20] and stimulates neutrophil proliferation, thereby increasing neutrophil counts and activity [21,22].

Like most medications, it has side effects. The side effects commonly observed are fatigue, headache, malaise, constipation, abdominal pain, decrease appetite, anemia, headache, thrombocytopenia, splenomegaly, and arthralgia [2,23]. It may also cause rare but important or life-threatening symptoms/conditions such as acute respiratory distress syndrome, anaphylaxis, capillary leak syndrome, decreased bone marrow density, hemoptysis, pulmonary alveolar hemorrhage, pulmonary infiltrates, sickle cell crisis, splenic rupture, Sweet syndrome, and vasculitis (aortitis) [2,23]. Glomerulonephritis and/or hematuria are among the rarest side effects, and these complications may be attributed to prolonged use of Filgrastim [2,23,24]. Acute glomerulonephritis is defined as the sudden onset of hematuria and proteinuria and Red Blood Cell (RBC) cast in urine [25].

We report a 7-year-old boy who experienced one of its rarest side effects at an unexpected time interval. The patient developed a rare and atypical occurrence of acute hematuria after receiving only his third dose of Filgrastim.

2. CASE REPORT

A 7-year-old boy presented to a local hospital with purpuric and petechial rashes all over his body, especially in his extremities with easy bruising, but without fever, vomiting, or active bleeding. Blood investigations revealed a low platelet count (4000 platelets/µL). However, the hemoglobin (12.2 g/dL), White Blood Cell (WBC; 6.8 × 10^3/µL), RBC (4.1 × 10^12/µL), and neutrophil (3.5 × 10^9/µL) counts were normal. Hence, the patient was diagnosed to have immune thrombocytopenic purpura. He was given two doses of immunoglobulins, after which his platelet count rose to 17,000/µL on day 4 and then back to 4000/µL on day 5.

On day 5, the patient was transferred to our hospital. Upon presentation, he was awake, alert, still with petechiae but with no active bleeding; other observations included absence of fever, clear chest with no sound, abdomen was soft, relaxed, and no organomegaly. His laboratory workup was repeated, and results showed pancytopenia with a WBC count of 2.5 × 10^3/µL, RBC count, 3.48 × 10^12/µL, hemoglobin, 10.2 g/dL; and neutrophils, 1.5 × 10^9/µL (Figure 1). The next day, he had an episode of epistaxis,
for which he was given platelets transfusion and was started on tranexamic acid and ceftriaxone because of his low neutrophil count. On day 10, he spiked once while waiting for bone marrow aspiration to be done. Laboratory tests were repeated on day 11, and results showed the same downward trend for hemoglobin (8.1 g/dL) and neutrophils (0.18 × 10^9/µL), with a platelet count of only 8000/µL. Another platelet transfusion was given on the same day.

On day 14, bone marrow aspiration was performed, and then the patient was started on high doses of dexamethasone for 4 days. On day 17, upon completion of dexamethasone doses, Complete Blood Count (CBC) was repeated, and results were as follows: hemoglobin, 10.1 g/dL; platelets, 2000/µL; and neutrophils, 0.24 × 10^9/µL (Figure 1).

On day 19, the patient was started on Filgrastim (G-CSF) at 5 µg/kg/dose once daily. However, later in the evening he developed abdominal pain, which was an expected side effect of Filgrastim. Other causes of abdominal pain were ruled out by abdomen ultrasound, and surgical referral was done, which was unremarkable. On day 21, the CBC test was repeated, and results continued to show pancytopenia with neutrophils decreasing to as low as 0.09 × 10^9/µL. Hence, the dose of Filgrastim was increased to 7.5 µg/kg/dose. The next day, the patient complained of red urine (hematuria), which was confirmed by urine analysis, showing RBC >50/hpf (Table 1). The intervention was made by reducing the dose of Filgrastim. As a result, his hematuria improved symptomatically, which was confirmed by repeated urine analysis.

![CBC Vs Days](image)

**Figure 1** Complete blood cell count over days of admission. Hb, hemoglobin.

| Urine analysis parameter | Day 2 of admission | Day 21 of admission (Day 3 of Filgrastim) | Day 22 of admission (Day 4 of Filgrastim) |
|--------------------------|-------------------|----------------------------------------|----------------------------------------|
| Urine color              | Yellow            | Bloody                                 | Light reddish                         |
| Appearance               | Slightly turbid   | Hazy                                  | Hazy                                  |
| Urine gravity            | 1.02              | 1.015                                  | 1.005                                  |
| Urine pH                 | 7.5               | 8                                      | 6                                      |
| Urine nitrate            | Nil               | Nil                                    | Nil                                    |
| Urine protein            | Nil               | +                                      | Nil                                    |
| Urine glucose            | Nil               | Nil                                    | Nil                                    |
| Urine ketone             | Nil               | Nil                                    | Nil                                    |
| Urine WBCs               | 0–2/hpf           | 2–5 hpf                                | 0–2 hpf                               |
| Urine leukocyte          | Nil               | Nil                                    | Trace                                  |
| Urine RBCs               | 1–2/hpf           | >50/hpf                                | 10–15/hpf                             |
| Urine bacteria           | Nil               | Nil                                    | Nil                                    |
| Urine epithelial cell    | Nil               | Nil                                    | Nil                                    |
| Urine blood              | Nil               | +++                                    | +++                                    |

**Table 1** Urine analysis prior to and during Filgrastim use

### 3. DISCUSSION

In this report, the authors present a case of a 7-year-old boy who was administered Filgrastim for a total of 5 days, and reported the development of hematuria and proteinuria on day 3 of the therapy. These side effects are worth noting because they are among the rarest to occur after following Filgrastim therapy, and more significantly, in this case, they occurred after the patient received his third dose. This is atypical and is worth consideration given that these side effects reported in the literature occur only after long-term use of Filgrastim and has not previously been reported in the literature occurring this early in the course of the treatment.

This case is unique, because of the early occurrence of hematuria and proteinuria in Filgrastim therapy. While the evidence has shown the occurrence of side effects after long-term use of Filgrastim, there is no prior evidence showing these Filgrastim-related side effects.

In their study, Dale et al. [26] enrolled a total of 853 patients with severe chronic neutropenia who received G-CSF almost daily or on alternate days. Glomerulonephritis and/or persistent hematuria were reported in 25 patients. Of these 25 patients, the symptoms of 12 patients were associated with underlying conditions. In the remaining 13 patients, symptoms resolved in five out of 10 patients for whom the dose of Filgrastim was reduced or discontinued. In two of the remaining three patients for whom the same dose was continued, the renal symptoms resolved [26].

Meanwhile, Sotomatsu et al. [24] reported a single case of a 12-year-old boy diagnosed with severe chronic neutropenia at the age of 5 months. He was started with G-CSF at the age of 5 years. Seven years after starting G-CSF, he developed hematuria for the first time at the age of 12 years, and a month later he was diagnosed as having rapid progressing glomerulonephritis. Filgrastim was continued with steroids, cyclophosphamide, warfarin, and dipyridamole. His creatinine levels decreased and creatinine clearance was improved but proteinuria persisted [24].

### 4. CONCLUSION

Filgrastim may cause early-onset hematuria and proteinuria during the course of treatment. Stopping and discontinuing the Filgrastim therapy may not be the best intervention for patients who are expected to take a longer course of this medication. Reducing the dose or continuing the same dose combined with monitoring the patients with the Kidney Function Test (KFT) is preferred. A kidney biopsy may be recommended in cases of worsening KFTs.

**CONFLICTS OF INTEREST**

The authors declare they have no conflicts of interest.

**AUTHORS’ CONTRIBUTION**

SA and HE contributed in conceptualization, designing and writing which includes review and editing the manuscript. SA, FH and AH contributed in formal analysis and writing the original draft. HE supervised the project. However, all the authors review the manuscript and approve the final draft of the manuscript.
REFERENCES

[1] U.S. Food & Drug Administration. Drugs@FDA: FDA-approved drugs. n.d. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&Ap-plNo=103353.

[2] Amgen. Neupogen (Filgrastim) injection prescribing information. Thousand Oaks, CA: Amgen; 2015.

[3] Bronchud MH, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, et al. Phase II/III study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987;56:809–13.

[4] Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164–70.

[5] Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988;318:1414–22.

[6] Israel DS, Plaisance KL. Neutropenia in patients infected with human immunodeficiency virus. Clin Pharm 1991;10:268–79.

[7] Hollingshead LM, Goa KL. Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 1991;42:300–30.

[8] Sheridan WP, Morstyn G, Wolf M, Dodds A, Lusk J, Maher D, et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989;2:891–5.

[9] Goldstone AH, Khwaja A. The role of haemopoietic growth factors in bone marrow transplantation. Leuk Res 1990;14:721–9.

[10] Migliaccio AR, Migliaccio G, Dale DC, Hammond WP. Hematopoietic progenitors in cyclic neutropenia: effect of granulocyte colony-stimulating factor in vivo. Blood 1990;75:1951–9.

[11] Wodzinski MA, Hampton KK, Reilly JT. Differential effect of G-CSF and GM-CSF in acquired chronic neutropenia. Br J Haematol 1991;77:249–50.

[12] Lang CH, Bagby GJ, Dobrescu C, Nelson S, Spitzer JJ. Effect of granulocyte colony-stimulating factor on sepsis-induced changes in neutrophil accumulation and organ glucose uptake. J Infect Dis 1992;166:336–43.

[13] Dührsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074–81.

[14] Lord BI, Bronchud MH, Owens S, Chang J, Howell A, Souza LA, et al. The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci U S A 1989;86:9499–503.

[15] Cohen AM, Zsebo KM, Inoue H, Hines D, Boone TC, Chazin VR, et al. In vivo stimulation of granulopoiesis by recombinant human granulocyte colony-stimulating factor. Proc Natl Acad Sci U S A 1987;84:2484–8.

[16] Nagata S, Tsuchiya M, Asano S, Kaziro Y, Yamazaki T, Yamamoto O, et al. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 1986;319:415–18.

[17] Morstyn G, Burgess AW. Hematopoietic growth factors: a review. Cancer Res 1988;48:5624–37.

[18] Metcalf D. The colony stimulating factors. Discovery, development, and clinical applications. Cancer 1990;65:2185–95.

[19] Groopman JE, Molina JM, Scadden DT. Hematopoietic growth factors. Biology and clinical applications. N Engl J Med 1989;321:1449–59.

[20] Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991;78:2791–808.

[21] Lieschke GJ, Morstyn G. Role of G-CSF and GM-CSF in the prevention of chemotherapy-induced neutropenia. In: Mertelsmann R, Herrmann F, editors. Hematopoietic growth factors in clinical applications. New York: Marcel Dekker Inc.; 1990, pp. 191–223.

[22] Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med 1992;327:28–35.

[23] Sandoz. Zarxio (Filgrastim-sndz) injection prescribing information. Princeton, NJ: Sandoz Inc.; 2015.

[24] Sotomatsu M, Kanazawa T, Ogawa C, Watanabe T, Morikawa A. Complication of rapidly progressive glomerulonephritis in severe congenital neutropenia treated with long-term granulocyte colony-stimulating factor (Filgrastim). Br J Haematol 2000;110:234–5.

[25] Stöppler MC. Medical definition of acute glomerulonephritis. San Clemente, CA, USA: MedicineNet; 2018. Available from: https://www.medicinenet.com/script/main/art.asp?articlekey=190465.

[26] Dale DC, Cottle TE, Fier CJ, Bolyard AA, Bonilla MA, Boxer LA, et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 2003;72:82–93.